Mayo Clin Proc Innov Qual Outcomes. 2022 Aug 8. doi: 10.1016/j.mayocpiqo.2022.07.004. Online ahead of print.
ABSTRACT
Corticosteroid therapy is the standard of care for all patients hospitalized with severe coronavirus disease 2019 (COVID-19), but the studies demonstrating mortality benefit were not designed to detect adverse effects of corticosteroids. To determine the severity of corticosteroid-induced hyperglycemia in patients with and without diabetes mellitus, we retrospectively collected data from the medical records of patients hospitalized with COVID-19 before and after corticosteroids were the standard of care. We demonstrate that corticosteroid-induced hyperglycemia is more severe in patients hospitalized with COVID-19 who have diabetes compared to those without diabetes. We also show that patients with diabetes require more doses of correctional insulin per day when on corticosteroid therapy. These data suggest that intensive point-of-care glucose monitoring could be limited in patients without diabetes mellitus and support cautionary use of corticosteroids in patients with COVID-19 discharged with supplemental oxygen.
PMID:35966031 | PMC:PMC9359482 | DOI:10.1016/j.mayocpiqo.2022.07.004